Form 8-K

Send us Feedback

ABIOMED (ABMD)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

Annual Reports

Quarterly Reports

8-K

8-K (Nov 19, 2012)8-K (Nov 13, 2012)8-K (Nov 1, 2012)8-K (Sep 21, 2012)8-K (Sep 12, 2012)8-K (Aug 14, 2012)8-K (Aug 2, 2012)8-K (Jul 27, 2012)8-K (May 29, 2012)8-K (May 22, 2012)8-K (May 16, 2012)8-K (Feb 3, 2012)8-K (Jan 23, 2012)8-K (Dec 23, 2011)8-K (Nov 3, 2011)8-K (Aug 16, 2011)8-K (Aug 4, 2011)8-K (Jun 2, 2011)8-K (May 18, 2011)8-K (May 13, 2011)8-K (Apr 5, 2011)8-K (Mar 11, 2011)8-K (Feb 3, 2011)8-K (Dec 20, 2010)8-K (Dec 8, 2010)8-K (Nov 4, 2010)8-K (Aug 31, 2010)8-K (Aug 17, 2010)8-K (Aug 4, 2010)8-K (Jun 28, 2010)8-K (Jun 9, 2010)8-K (Jun 4, 2010)8-K (May 19, 2010)8-K (Feb 4, 2010)8-K (Jan 7, 2010)8-K (Nov 5, 2009)8-K (Aug 6, 2009)8-K (Jul 31, 2009)8-K (Jul 22, 2009)8-K (Jun 3, 2009)8-K (May 18, 2009)8-K (May 12, 2009)8-K (Apr 23, 2009)8-K (Apr 21, 2009)8-K (Feb 5, 2009)8-K (Dec 22, 2008)8-K (Dec 19, 2008)8-K (Nov 10, 2008)8-K (Oct 14, 2008)8-K (Oct 3, 2008)8-K (Oct 2, 2008)8-K (Aug 22, 2008)8-K (Aug 20, 2008)8-K (Aug 18, 2008)8-K (Aug 7, 2008)8-K (Aug 6, 2008)8-K (Jul 30, 2008)8-K (Jul 3, 2008)8-K (Jul 2, 2008)8-K (Jun 26, 2008)8-K (Jun 2, 2008)8-K (May 30, 2008)8-K (May 22, 2008)8-K (May 21, 2008)8-K (Mar 28, 2008)8-K (Feb 7, 2008)8-K (Jan 24, 2008)8-K (Jan 7, 2008)8-K (Dec 21, 2007)8-K (Dec 17, 2007)8-K (Dec 12, 2007)8-K (Nov 8, 2007)8-K (Oct 11, 2007)8-K (Aug 30, 2007)8-K (Aug 14, 2007)8-K (Aug 9, 2007)8-K (Jul 3, 2007)8-K (Jun 15, 2007)8-K (May 31, 2007)8-K (May 17, 2007)8-K (Apr 23, 2007)8-K (Apr 2, 2007)8-K (Mar 26, 2007)8-K (Mar 21, 2007)8-K (Feb 5, 2007)8-K (Dec 21, 2006)8-K (Dec 8, 2006)8-K (Nov 16, 2006)8-K (Nov 14, 2006)8-K (Nov 8, 2006)8-K (Oct 13, 2006)8-K (Sep 8, 2006)8-K (Sep 5, 2006)8-K (Aug 8, 2006)8-K (Jun 28, 2006)8-K (Jun 1, 2006)8-K (May 25, 2006)8-K (May 12, 2006)8-K (May 8, 2006)8-K (Feb 3, 2006)8-K (Feb 2, 2006)8-K (Jan 20, 2006)8-K (Jan 18, 2006)8-K (Dec 19, 2005)8-K (Dec 5, 2005)8-K (Nov 2, 2005)8-K (Oct 21, 2005)8-K (Oct 4, 2005)8-K (Aug 15, 2005)8-K (Aug 10, 2005)8-K (Aug 4, 2005)8-K (Jul 27, 2005)8-K (Jun 30, 2005)8-K (Jun 15, 2005)8-K (May 31, 2005)8-K (May 16, 2005)8-K (May 9, 2005)8-K (May 5, 2005)8-K (May 3, 2005)8-K (Apr 26, 2005)8-K (Jan 31, 2005)8-K (Jan 12, 2005)8-K (Nov 1, 2004)8-K (Oct 26, 2004)8-K (Sep 8, 2004)8-K (Jul 30, 2004)8-K (May 27, 2004)8-K (Apr 8, 2004)8-K (Feb 10, 2004)8-K (Dec 10, 2003)8-K (Oct 30, 2003)8-K (Aug 11, 2003)8-K (Oct 24, 2002)8-K (Jun 6, 2002)8-K (Dec 6, 2001)8-K (Jan 31, 2001)8-K (Oct 16, 2000)8-K (Aug 14, 2000)8-K (Dec 3, 1999)8-K (Aug 25, 1997)8-K (Jul 31, 1996)8-K (Aug 11, 1995)

Other

ABIOMED 8-K 2012

Documents found in this filing:

Form 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 22, 2012

ABIOMED, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

0-20584

04-2743260

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

22 Cherry Hill Drive

Danvers, MA 01923

(Address of principal executive offices) (Zip Code)

(978) 646-1400

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On May 22, 2012, our compensation committee made its annual compensation determinations for our named executive officers. The committee determined the bonuses for fiscal 2012 performance, the salaries and target bonuses for fiscal 2013, granted stock options and made performance share awards in the form of restricted stock units to executive officers. The compensation decisions made with respect to our executive officers who are serving as our principal executive officer, principal financial officer, or who were named executive officers in our most recent proxy statement were as follows:


Executive Officer	Fiscal 2012 Bonus		Fiscal 2013 Salary		Target Fiscal 2013 Bonus (Percentage of salary)			Shares Underlying Stock Options (4 year vesting)		Shares Underlying Restricted Stock Units (time based vesting)		Target Shares Underlying Restricted Stock Units (time and performance based vesting)

Michael R. Minogue, Chairman, CEO and President	$	634,761	$	506,927		120	%		100,000		17,000		51,000

Robert L. Bowen, Chief Financial Officer	$	137,103	$	310,767		50	%		20,000		5,000		9,000

David Weber, Chief Operating Officer	$	190,575	$	333,506		65	%		25,000		6,500		13,500

William J. Bolt, Senior VP, Engineering and Quality Assurance	$	141,398	$	277,655		55	%		20,000		5,000		11,250

Michael G. Howley, VP and General Manager, Global Sales and Marketing	$	189,108	$	278,409		60	%		25,000		5,000		12,750

The performance share awards of time based restricted stock units vest in three equal installments annually over three years. The performance share awards of performance and time based restricted stock units have a double trigger vesting pursuant to which 2013 revenue performance will determine whether 0%, or a ratable amount from 33% to 100% of the underlying restricted stock units are eligible for vesting, at which point half of the units eligible for vesting will vest on the second anniversary of the date of grant and the other half of the units eligible for vesting will vest on the third anniversary of the date of grant. The stock options granted vest 25% per year on each of the first four anniversaries of the date of grant.

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


ABIOMED, Inc.

By:		/s/ Robert L. Bowen
		Robert L. Bowen
		Vice President and Chief Financial Officer

Date: May 29, 2012

- 3 -

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs

ABIOMED (ABMD)

Annual Reports

Quarterly Reports

8-K

Other

Documents found in this filing: